Aptose shareholders approved the continuance of the Company from the Canada Business Corporations Act to the Business Corporations Act (Alberta) and the plan of arrangement for acquisition by HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd. Under the terms, Aptose shareholders (excluding Hanmi Purchasers and affiliates) will receive C$2.41 in cash per Common Share, representing a 28% premium over Aptose's 30-day VWAP of C$1.88 on the Toronto Stock Exchange. The Court of Kings Bench of Alberta has issued a final order approving the Arrangement, with closing expected by the end of April 2026, subject to customary closing conditions including regulatory approvals. Aptose presented positive clinical data for its tuspetinib (TUS)+venetoclax (VEN)+azacitidine (AZA) triplet therapy in newly diagnosed AML patients at the ASH 2025 Annual Meeting. The TUS+VEN+AZA triplet demonstrated 90% high-quality clinical responses (CR/CRh) across 40 mg, 80 mg, and 120 mg dose levels, and 100% at the higher 80 mg and 120 mg dose levels, with 78% MRD negativity in responding subjects. The therapy was well tolerated with no dose-limiting toxicities (DLTs) across all evaluable TUS dose levels, no drug-related deaths, differentiation syndrome, QTc prolongation, or CPK elevation reported. Net loss for the year ended December 31, 2025, was $25.5 million, a slight increase from $25.4 million for the comparable period in 2024. Cash, cash equivalents, restricted cash, and restricted cash equivalents totaled $4.1 million as of December 31, 2025. The company does not have sufficient cash to fund operations and relies on advances made by Hanmi, which provided over US$41 million in debt facilities over the past 18 months. Research and development expenses decreased by $3.8 million to $11.3 million for the year ended December 31, 2025, primarily due to the conclusion of APTIVATE clinical trial activities and lower manufacturing costs for tuspetinib, as well as lower headcount.